Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats

British Journal of Pharmacology

Volumn 158, Issue 5, 2009, Pages 1210-1226

  Painsipp, Evelin ^a   Shahbazian, Anaid ^a   Hölzer, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

5 hydroxytryptamine; Alosetron; Cilansetron; Clonidine; Colonic blood flow; Mesenteric blood flow; Mesenteric vasoconstriction; N nitro larginine methylester; Nitric oxide; Tegaserod; Vascular conductance

Indexed keywords

ALOSETRON; CILANSETRON; TEGASEROD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; COLITIS; COLON BLOOD FLOW; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART HEMODYNAMICS; HEART RATE; INTESTINE PRESSURE; MESENTERY BLOOD FLOW; NONHUMAN; PRIORITY JOURNAL; RAT; SPLANCHNIC BLOOD FLOW; SUPERIOR MESENTERIC ARTERY; TRANSVERSE COLON; VASOCONSTRICTION;

EID: 70849120127     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00392.x     Document Type: Article

References (55)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M (2008). Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 6: 545-555.
3. Arndts D, DoevendansJ, Kirsten R, Heintz B (1983). New aspects of the pharmacokinetics and pharmacodynamics of Clonidine in man. Eur J Clin Pharmacol 24: 21-30. (Pubitemid 13181781)
4. 2B receptor antagonist in vitro and in vivo. Br J Pharmacol 143: 549-560.
5. Beck IT (2001). Possible mechanisms for ischemic colitis during alosetron therapy. Gastroenterology 121: 231-232. (Pubitemid 32591535)
6. Bercik P, Verdu EF, Collins SM (2005). Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 34: 235-245. (Pubitemid 40615953)
7. Bohlen HG, Henrich H, Gore RW, Johnson PC (1978). Intestinal muscle and mucosal blood flow during direct sympathetic stimulation. Am J Physiol 235: H40-H45. (Pubitemid 9164977)
8. Brinker AD, Mackey AC, Prizont R (2004). Tegaserod and ischemic colitis. N Engl J Med 351: 1361-1364.
9. 3antagonist treatment? Neurogastroenterol Motil 19: 77-84.
10. Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE et al (2002). Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123: 425-432. (Pubitemid 34827186)
11. Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P (2006). Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 101: 1069-1079. (Pubitemid 43725322)
12. Chang L, Kahler KH, Sarawate C, Quimbo R, Kralstein J (2008). Assessment of potential risk factors associated with ischaemic colitis. Neurogastroenterol Motil 20: 36-42. (Pubitemid 350277442)
13. Chey WD, Cash BD (2005). Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Expert Opin Investig Drugs 14: 185-193. (Pubitemid 40403392)
14. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H et al. (2004). Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126: 1657-1664. (Pubitemid 38736329)
15. De Giorgio R, Barbara G (2008). Is irritable bowel syndrome an inflammatory disorder? Curr Gastroenterol Rep 10: 385-390.
16. De Ponti F (2004). Pharmacology of serotonin: what a clinician should know. Gut 53: 1520-1535. (Pubitemid 39272827)
17. DiBaise JK (2005). Tegaserod-associated ischemic colitis. Pharmacotherapy 25: 620-625.
18. Emmanuel AV, Kamm MA (2000). Laser Doppler flowmetry as a measure of extrinsic colonic innervation in functional bowel disease. Gut 46: 212-217.
19. Evans BW, Clark WK, Moore DJ, Whorwell PJ (2007). Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev issue 4, article number: CD003960.
20. Gardiner SM, Compton AM, Kemp PA, Bennett T (1990). Regional and cardiac haemodynamic effects of N-nitro-L-arginine methyl ester in conscious Long Evans rats. Br J Pharmacol 101: 625-631. (Pubitemid 20357186)
21. Gershon MD, Tack J (2007). The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132: 397-414.
22. Glatzle J, Sternini C, Robin C, Zittel TT, Wong H, Reeve JR et al. (2002).
23. 3receptors in the rat gastrointestinal tract. Gastroenterology 123: 217-226.
24. Gore RW, Bohlen HG (1977). Microvascular pressures in rat intestinal muscle and mucosal villi. Am J Physiol 233: H685-H693.
25. Granger DN, Richardson PDI, Kvietys PR, Mortillaro NA (1980). Intestinal blood flow. Gastroenterology 78: 837-863.
26. 3receptor blockade on colonic haemodynamic responses to ischaemia and reperfusion in the rat. Neurogastroenterol Motil 19: 607-616.
27. Gul H, Yildiz O, Simsek A, Balkan M, Ersoz N, Cetiner S et al. (2003). Pharmacologic characterization of contractile serotonergic receptors in human isolated mesenteric artery. J Cardiovasc Pharmacol 41: 307-315. (Pubitemid 36135257)
28. Guth PH, Leung FW (1987). Physiology of the gastric circulation. In: Johnson LR (ed.). Physiology of The Gastrointestinal Tract, Second Edition. Raven Press: New York, pp. 1031-1053.
29. Heinemann A, Wachter CH, Holzer P (1998). Differential regulation of mesenteric and femoral blood flow in the rat as revealed by computerized data acquisition and evaluation. J Auton Pharmacol 18: 39-48. (Pubitemid 28374718)
30. Heinemann A, Sattler V, Jocic M, Wienen W, Holzer P (1999). Effect of angiotensin II and telmisartan, an angiotensinl receptor antagonist, on rat gastric mucosal blood flow. Aliment Pharmacol Ther 13: 347-355. (Pubitemid 29142044)
31. Higgins PD, Davis KJ, Laine L (2004). Systematic review: the epidemiology of ischaemic colitis. Aliment Pharmacol Ther 19: 729-738. (Pubitemid 38496638)
32. Hölzer P (2006). Neural regulation of gastrointestinal blood flow. In: Johnson LR (ed.). Physiology of the Gastrointestinal Tract, Fourth Edition. Academic Press: New York, pp. 817-839.
33. Holzer P, Painsipp E (2001). Differential effects of Clonidine, dopamine, dobutamine, and dopexamine on basal and acid-stimulated mucosal blood flow in the rat stomach. Crit Care Med 29: 335-343. (Pubitemid 32171779)
34. Holzer P, Livingston EH, Guth PH (1991). Sensory neurons signal for an increase in rat gastric mucosal blood flow in the face of pending acid injury. Gastroenterology 101: 416-423.
35. Hölzer P, Wachter C, Jocic M, Heinemann A (1994). Vascular beddependent roles of the peptide CGRP and nitric oxide in acidevoked hyperaemia of the rat stomach. J Physiol (London) 480: 575-585. (Pubitemid 24340959)
36. Holzer P, Painsipp E, Jocic M, Heinemann A (2003a). Acid challenge delays gastric pressure adaptation, blocks gastric emptying and stimulates gastric fluid secretion in the rat. Neurogastroenterol Motil 15: 45-55. (Pubitemid 36313134)
37. Holzer P, Painsipp E, Weber E, Pfannkuche HJ (2003b). 5-HT3 receptor antagonists, alosetron and cilansetron, impair mesenteric blood flow in rats. Gastroenterology 124 (Suppl. 1): A148-A149.
38. Johansson K (1988). Gastrointestinal application of laser Doppler flowmetry. An experimental and clinical study in cat and man. Acta Chir Scand Suppl 545: 1-64.
39. Krawisz JE, Sharon P, Stenson WF (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity.
40. Assessment of inflammation in rat and hamster models. Gastroenterology 87: 1344-1350.
41. Leung FW, Guth PH, Scremln OU, Golanska EM, Kauffman GL (1984). Regional gastric mucosal blood flow measurements by hydrogen gas clearance in the anesthetized rat and rabbit. Gastroenterology 87: 28-36.
42. Livingston EH, Reedy T, Leung FW, Guth PH (1989). Computerized curve fitting in the analysis of hydrogen gas clearance curves. Am J Physiol 257: G668-G675. (Pubitemid 19263598)
43. Martin GR (1994). Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacol Ther 62: 283-324. (Pubitemid 24248421)
44. Miller DP, Alfredson T, Cook SF, Sands BE, Walker AM (2003). Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Am J Gastroenterol 98: 1117-1122. (Pubitemid 36733776)
45. Ni W, Geddes TJ, Priestley JR, Szasz T, Kuhn DM, Watts SW (2008). The existence of a local 5-hydroxytryptaminergic system in peripheral arteries. Br J Pharmacol 154: 663-674. (Pubitemid 351744942)
46. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R (1990). A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702. (Pubitemid 20069706)
47. Potenza MA, Serio M, Montagnani M, Mansi G, Rinaldi R, Genualdo M et al. (1998). Functional evaluation of 5-hydroxytryptamine receptor activity in rat resistance vessels. J Auton Pharmacol 18: 75-81. (Pubitemid 28365992)
48. Rahiml R, Nikfar S, Abdollahi M (2008). Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 30: 884-901. (Pubitemid 351802282)
49. Reed DE, Vanner SJ (2003). Long vasodilator reflexes projecting through the myenteric plexus in guinea-pig ileum. J Physiol (London) 553: 911-924.
50. Rivkin A (2003). Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review. Clin Ther 25: 1952-1974. (Pubitemid 36936591)
51. Schoenfeld P (2004). Review article: the safety profile of tegaserod. Aliment Pharmacol Ther 20 (Suppl. 7): 25-30. (Pubitemid 39657673)
52. Spiller RC (2007). Irritable bowel syndrome: bacteria and inflammation - clinical relevance now. Curr Treat Options Gastroenterol 10: 312-321. (Pubitemid 47193515)
53. Wager-Page SA, Ghazali B, Anderson W, Veale WL, Davison JS (1992). Neuropeptide Y, peptide YY, and pancreatic polypeptide modulate duodenal and colonic motility at a thoracic spinal site in rats. Peptides 13: 807-813.
54. Weber E, Hamel CT, Bernhard M, Pfannkuche HJ (2006). Tegaserod has no potential for vasoconstriction or impairment of vasodilatation in isolated human and non-human primate mesenteric arteries. Gastroenterology 130 (Suppl. 2): A-489.
55. Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stubbins M et al. (2004). Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 53: 1452-1458. (Pubitemid 39265265)